Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000075381
Ethics application status
Approved
Date submitted
9/05/2015
Date registered
13/01/2017
Date last updated
1/02/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of shock waves in the treatment of chronic wounds.
Scientific title
Clinical, pathomorphological, immunocytochemical and molecular characterization of the effects of extracorporeal shock waves (ESW) in patients with chronic wounds: a prospective, single-blinded, placebo-controlled, randomized clinical study with an in vivo and in vitro comparison.
Secondary ID [1] 286673 0
None
Universal Trial Number (UTN)
Trial acronym
SHOWN - SHOck Waves in wouNds
Linked study record

Health condition
Health condition(s) or problem(s) studied:
chronic pressure ulcers 295014 0
chronic diabetic ulcer 301142 0
chronic venous ulcers 301143 0
Condition category
Condition code
Physical Medicine / Rehabilitation 295277 295277 0 0
Physiotherapy
Skin 300905 300905 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
ESW with a planar (electromagnetic) or radial (pneumatic) ESW applicator will be administered once to Group I, and three times to Group II at one session per week for three weeks. Methodology and parameters of the active ESW stimulation will be set in accordance to the literature data for clinical trials, as follows: energy flux density (EFD) of 0.10 mJ/mm2, pressure (P) of 2,5 bars, the number of pulses will be depended on the ulcer size, with basically 300 pulses plus additional 100 impulses/cm2 of wound area with a frequency (f) of 5 Hz (duration ranged of 10-15 minutes). In the placebo in vivo group, the sham-ESW stimulation will be made without the biologically active component with using the special polyethylene cover at the top of ESW applicator heading to absorb the energy and limit its propagation towards patient's tissue.

The in vitro single ESW stimulation will be performed with the same ESW applicators, as for an in vivo intervention. Methodology of the active ESW stimulation will be set in accordance to the literature data for in vitro studies. We are going to use a various combinations of ESW parameters to determine the mechanism of biological action and to show the distinct border between positive and harmful ESW effect, as follows: EFD of 0.10, 0,20 or 0,50 mJ/mm2, pressure (P) of 2,5, 3,5 or 5,0 bars, the number of different pulses number (100, 200, 300, 500, 5000) with frequency (f) of 1 or 5 Hz (duration ranged of 10-20 minutes). In the placebo in vitro group, the sham-ESW will be conducted and the cells will be not exposed to ESW, but will be maintained outside of the incubator with the device off but in contact with the plates for the same period of time.

Biopsies from the wounds will be obtained from all patients qualified into study. The resulting biopsies will be used in pathomorphological and immunocytochemical tests of wound tissues, and will provide sufficient material to develop primary cell cultures. On the other hand, the in vitro testing will be conducted on the basis of primary cultures of human skin fibroblasts obtained by biopsy before the ESW stimulation, from wound tissue.
Intervention code [1] 291822 0
Rehabilitation
Intervention code [2] 291823 0
Treatment: Devices
Comparator / control treatment
Placebo for both, in vivo and in vitro studies.
Control group
Placebo

Outcomes
Primary outcome [1] 295020 0
First primary outcome is a clinical observation in vivo of size area of wound measured by digital planimetry, temperature distribution of wound measured by infrared thermal imaging camera, and pain intensity of wound assessed by Visual Analogue Scale.
Timepoint [1] 295020 0
Immediately before and after ESW stimulation, as well as follow-up (2, 4 and 8 weeks).
Primary outcome [2] 300314 0
Second primary outcome are a pathomorphological and immunocytochemical observations in vivo based on wound tissue biopsy samples: cell proliferation, apoptosis and necrosis assessed using TUNEL scratch assay; microvasculature and angiogenesis (PECAM-1, ICAM, Ki-67) by microscopic evaluation; mechanotransduction of biological signaling assessed using RT-PCR techniques; and reorganization of the cytoskeleton and nucleooskeleton by microscopic evaluation .
Timepoint [2] 300314 0
Immediately before and after ESW stimulation, as well as follow-up (2, 4 and 8 weeks).
Secondary outcome [1] 314589 0
Secondary outcome are immunocytochemical and molecular observations in vitro based on cultured reference fibroblast cells: fibroblast and keratinocytes migration and differentiation assessed by in vitro sensitization assay; cells proliferative activity and their apoptosis assessed using TUNEL scratch assay; analysis of tissues growth factors (FGF1 i FGF2, TGF-beta1 and CTGF) evaluated using enzyme-linked immunosorbent assay; cell transformation to myofibroblasts measured by in vitro scratch assay; transcriptional coactivators and mechanotransduction using RT-PCR techniques.
Timepoint [1] 314589 0
Immediately before and after ESW stimulation.

Eligibility
Key inclusion criteria
1. Chronic wound (ChW) diagnosed as pressure, diabetic or venous etiology,
2. ChW surface area more than 3 cm2 of the ChW surface (due to do the biopsy) but less than 20 cm2 (to large area),
3. ChW duration more than 3 months (to be classified as a ChW), but less than 24 months (to be not classified as hard-to-heal),
4. ChW classified as 2nd grade (deep skin sore) or 3rd grade (the subcutaneous tissue damage with mild necrosis),
5. Obtain voluntary and informed consent of the patient to participate in the study.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Acute wounds (surgical, traumatic, burns),
2. ChW size area less than 3 cm2 and more then 20 cm2,
3. ChW duration less than 3 months and more then 24 months,
4. ChW infection clinically confirmed,
5. ChW classified as 1st or 4th grade,
6. ChW with necrotic or infection events,
7. Contraindications for ESW stimulation (pregnancy or ovulation, cancer or malignancy, electronic or metal implants, acute or recurrent inflammations, bleeding tendency),
8. The lack of informed consent,
9. Failure to comply with the study protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be done by sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a numbered envelopes.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The obtained results will be subjected to statistical analysis made with the STATISTICA software. Power analysis in each group will be required and calculated to establish the statistical significance with a = 0.05 and power = 0.80 based on the estimated outcomes of 85% for ESW. For measurable variables, the arithmetic mean, standard deviation, medians and extreme values (minimum and maximum) will be calculated. However for qualitative variables, the occurrence rates, will be expressed as a percentage. Homogeneity of the compared groups will be established in terms of selected characteristics of the participants, and the level of significance will be accepted at p>0.05. Results will be compared between the two groups with comparative tests (independent), as well as each group results obtained before and after ESW stimulation (dependent tests). The type of statistical tests for both, in vivo and in vitro data, will be depend on the fulfilment of their objectives. Statistically significant differences at p<0.05.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/02/2017
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment outside Australia
Country [1] 6869 0
Poland
State/province [1] 6869 0
Lower Silesia

Funding & Sponsors
Funding source category [1] 291249 0
University
Name [1] 291249 0
Wroclaw Medical University
Country [1] 291249 0
Poland
Primary sponsor type
University
Name
Foundation of the Wroclaw Medical University
Address
Mikulicza Radecki 5 Street
50-345 Wroclaw
Country
Poland
Secondary sponsor category [1] 293872 0
None
Name [1] 293872 0
Address [1] 293872 0
Country [1] 293872 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292811 0
Commission of Bioethics at the Wroclaw Medical University
Ethics committee address [1] 292811 0
Ethics committee country [1] 292811 0
Poland
Date submitted for ethics approval [1] 292811 0
21/11/2016
Approval date [1] 292811 0
29/12/2016
Ethics approval number [1] 292811 0
KB-632/2016

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 57130 0
Dr Robert Dymarek
Address 57130 0
Department of Nervous System Diseases, Wroclaw Medical University, Bartla 5 Street, 51-618 Wroclaw
Country 57130 0
Poland
Phone 57130 0
+48 723 895 770
Fax 57130 0
Email 57130 0
[email protected]
Contact person for public queries
Name 57131 0
Robert Dymarek
Address 57131 0
Department of Nervous System Diseases, Wroclaw Medical University, Bartla 5 Street, 51-618 Wroclaw
Country 57131 0
Poland
Phone 57131 0
+48 723 895 770
Fax 57131 0
Email 57131 0
[email protected]
Contact person for scientific queries
Name 57132 0
Robert Dymarek
Address 57132 0
Department of Nervous System Diseases, Wroclaw Medical University, Bartla 5 Street, 51-618 Wroclaw
Country 57132 0
Poland
Phone 57132 0
+48 723 895 770
Fax 57132 0
Email 57132 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe Immediate Clinical Effects Following a Single Radial Shock Wave Therapy in Pressure Ulcers: A Preliminary Randomized Controlled Trial of The SHOWN Project.2023https://dx.doi.org/10.1089/wound.2021.0015
N.B. These documents automatically identified may not have been verified by the study sponsor.